Literature DB >> 1313583

Vesicular stomatitis virus antigenic octapeptide N52-59 is anchored into the groove of the H-2Kb molecule by the side chains of three amino acids and the main-chain atoms of the amino terminus.

K Shibata1, M Imarai, G M van Bleek, S Joyce, S G Nathenson.   

Abstract

This study describes an analysis of the interaction of individual amino acid residues of the vesicular stomatitis virus (VSV) nucleocapsid antigenic octapeptide (N52-59; Arg-Gly-Tyr-Val-Tyr-Gln-Gly-Leu) with the H-2Kb molecule and T-cell receptors (TCRs). Tyr-3, Tyr-5, and Leu-8 were the positions in the peptide found to be H-2Kb contact residues by analyzing single alanine-substituted peptides in a competition assay with a Kb-restricted antigenic nonapeptide of Sendai virus. Arg-1, Gly-2, Val-4, Gln-6, and Gly-7 of the peptide were identified as putative TCR contact residues by testing the peptide analogs for their capacity to sensitize targets for VSV-specific cytolytic T-lymphocyte clones. The octamer N52-59 was the optimal length of the peptide required for binding to Kb. This peptide length requirement and the finding of an irregular interspersing of major histocompatibility complex and TCR contact residues are most consistent with the conclusion that the peptide is in an extended conformation in the antigen binding groove. Furthermore, data on binding of truncated peptides show that, although the Arg-1 side chain has been assigned as a TCR contact residue, the main-chain atoms of the N-terminal amino group are most likely involved in interacting with the major histocompatibility complex molecule. A panel of H-2Kb point mutants was constructed to explore the effect of altered amino acid residues on the binding of N52-59. Mutants with amino acid substitutions along the floor of the groove all bound the VSV peptide but modulated its interaction with Kb, apparently causing subtle changes in the spatial arrangement of some specific TCR contact residues in the peptide.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1313583      PMCID: PMC48819          DOI: 10.1073/pnas.89.7.3135

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  32 in total

Review 1.  Structure, function, and diversity of class I major histocompatibility complex molecules.

Authors:  P J Bjorkman; P Parham
Journal:  Annu Rev Biochem       Date:  1990       Impact factor: 23.643

2.  Crystallization and preliminary X-ray diffraction studies of the human major histocompatibility antigen HLA-B27.

Authors:  J C Gorga; D R Madden; J K Prendergast; D C Wiley; J L Strominger
Journal:  Proteins       Date:  1992-01

3.  Peptide selection by MHC class I molecules.

Authors:  T N Schumacher; M L De Bruijn; L N Vernie; W M Kast; C J Melief; J J Neefjes; H L Ploegh
Journal:  Nature       Date:  1991-04-25       Impact factor: 49.962

4.  Molecular mapping of a histocompatibility-restricted immunodominant T cell epitope with synthetic and natural peptides: implications for T cell antigenic structure.

Authors:  I Berkower; G K Buckenmeyer; J A Berzofsky
Journal:  J Immunol       Date:  1986-04-01       Impact factor: 5.422

5.  The epitopes of influenza nucleoprotein recognized by cytotoxic T lymphocytes can be defined with short synthetic peptides.

Authors:  A R Townsend; J Rothbard; F M Gotch; G Bahadur; D Wraith; A J McMichael
Journal:  Cell       Date:  1986-03-28       Impact factor: 41.582

6.  MHC class II region encoding proteins related to the multidrug resistance family of transmembrane transporters.

Authors:  E V Deverson; I R Gow; W J Coadwell; J J Monaco; G W Butcher; J C Howard
Journal:  Nature       Date:  1990 Dec 20-27       Impact factor: 49.962

7.  A gene in the human major histocompatibility complex class II region controlling the class I antigen presentation pathway.

Authors:  T Spies; M Bresnahan; S Bahram; D Arnold; G Blanck; E Mellins; D Pious; R DeMars
Journal:  Nature       Date:  1990 Dec 20-27       Impact factor: 49.962

8.  The structure of HLA-B27 reveals nonamer self-peptides bound in an extended conformation.

Authors:  D R Madden; J C Gorga; J L Strominger; D C Wiley
Journal:  Nature       Date:  1991-09-26       Impact factor: 49.962

9.  Molecular loss variants of the murine major histocompatibility complex: nonexpression of H-2K antigens associated with marked reduction in H-2K mRNA as determined by oligonucleotide hybridization analysis.

Authors:  R A Zeff; S S Geier; S G Nathenson
Journal:  J Immunol       Date:  1986-08-15       Impact factor: 5.422

10.  H-2Kd-restricted antigenic peptides share a simple binding motif.

Authors:  P Romero; G Corradin; I F Luescher; J L Maryanski
Journal:  J Exp Med       Date:  1991-09-01       Impact factor: 14.307

View more
  20 in total

1.  Isolation of an immunodominant viral peptide that is endogenously bound to the stress protein GP96/GRP94.

Authors:  T J Nieland; M C Tan; M Monne-van Muijen; F Koning; A M Kruisbeek; G M van Bleek
Journal:  Proc Natl Acad Sci U S A       Date:  1996-06-11       Impact factor: 11.205

2.  On defining the rules for interactions between the T cell receptor and its ligand: a critical role for a specific amino acid residue of the T cell receptor beta chain.

Authors:  F Wang; T Ono; A M Kalergis; W Zhang; T P DiLorenzo; K Lim; S G Nathenson
Journal:  Proc Natl Acad Sci U S A       Date:  1998-04-28       Impact factor: 11.205

3.  A general method for facilitating heterodimeric pairing between two proteins: application to expression of alpha and beta T-cell receptor extracellular segments.

Authors:  H C Chang; Z Bao; Y Yao; A G Tse; E C Goyarts; M Madsen; E Kawasaki; P P Brauer; J C Sacchettini; S G Nathenson
Journal:  Proc Natl Acad Sci U S A       Date:  1994-11-22       Impact factor: 11.205

4.  Differential thymic selection outcomes stimulated by focal structural alteration in peptide/major histocompatibility complex ligands.

Authors:  Y Ghendler; M K Teng; J H Liu; T Witte; J Liu; K S Kim; P Kern; H C Chang; J H Wang; E L Reinherz
Journal:  Proc Natl Acad Sci U S A       Date:  1998-08-18       Impact factor: 11.205

5.  Rubella virus-specific cytotoxic T-lymphocyte responses: identification of the capsid as a target of major histocompatibility complex class I-restricted lysis and definition of two epitopes.

Authors:  A E Lovett; C S Hahn; C M Rice; T K Frey; J S Wolinsky
Journal:  J Virol       Date:  1993-10       Impact factor: 5.103

6.  Specificity of the H-2 L(d)-restricted cytotoxic T-lymphocyte response to the mouse hepatitis virus nucleocapsid protein.

Authors:  C C Bergmann; S A Stohlman
Journal:  J Virol       Date:  1996-05       Impact factor: 5.103

7.  Crystal structure of the major histocompatibility complex class I H-2Kb molecule containing a single viral peptide: implications for peptide binding and T-cell receptor recognition.

Authors:  W Zhang; A C Young; M Imarai; S G Nathenson; J C Sacchettini
Journal:  Proc Natl Acad Sci U S A       Date:  1992-09-01       Impact factor: 11.205

8.  An immunodominant Kb-restricted peptide from the p15E transmembrane protein of endogenous ecotropic murine leukemia virus (MuLV) AKR623 that restores susceptibility of a tumor line to anti-AKR/Gross MuLV cytotoxic T lymphocytes.

Authors:  H D White; D A Roeder; W R Green
Journal:  J Virol       Date:  1994-02       Impact factor: 5.103

9.  Functional analysis of amino acid residues encompassing and surrounding two neighboring H-2Db-restricted cytotoxic T-lymphocyte epitopes in simian virus 40 tumor antigen.

Authors:  J D Lippolis; L M Mylin; D T Simmons; S S Tevethia
Journal:  J Virol       Date:  1995-05       Impact factor: 5.103

10.  Viral adaptation to immune selection pressure by HLA class I-restricted CTL responses targeting epitopes in HIV frameshift sequences.

Authors:  Christoph T Berger; Jonathan M Carlson; Chanson J Brumme; Kari L Hartman; Zabrina L Brumme; Leah M Henry; Pamela C Rosato; Alicja Piechocka-Trocha; Mark A Brockman; P Richard Harrigan; David Heckerman; Daniel E Kaufmann; Christian Brander
Journal:  J Exp Med       Date:  2010-01-11       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.